Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

Journal of the American Academy of Dermatology

Volumn 41, Issue 6, 1999, Pages 1002-1007

  Beutner, K R ^a   Geisse, J K ^a   Helman, D ^a   Fox, T L ^a   Ginkel, A ^a   Owens, M L ^a  

^a Solano Dermatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DRUG VEHICLE; IMIQUIMOD; INTERFERON;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032694077     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(99)70261-6     Document Type: Article

References (24)

1. LA Drake RI Ceilley RL Cornelison WA Dobes W Dorner RW Goltz Guidelines of care for basal cell carcinoma J Am Acad Dermatol 26 1992 117 120
2. C Marwick New light on skin cancer mechanisms JAMA 274 1995 445 446
3. DS Preston RS Stern Nonmelanoma cancers of the skin N Engl J Med 327 1992 1649 1662
4. TL Testerman JF Gerster LM Imbertson MJ Reiter RL Miller SJ Gibson Cytokine induction by the immunomodulators imiquimod and S-27609 J Leukoc Biol 58 1995 365 372
5. HB Slade ML Owens MA Tomai RL Miller Imiquimod 5% cream (Aldara) Exp Opin Invest Drugs 7 1998 437 449
6. LM Imbertson JM Beaurline AM Couture SJ Gibson RM Smith RL Miller Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463 J Invest Dermatol 110 1998 734 739
7. KR Beutner SL Spruance AJ Hougham TL Fox ML Owens JM Douglas Jr Treatment of genital warts with an immune-response modifier (imiquimod) J Am Acad Dermatol 38 1998 230 239
8. KR Beutner SK Tyring KR Trofatter JM Douglas Jr SL Spruance ML Owens Imiquimod, a patient applied immune response modifier for treatment of external genital warts Antimicrob Agents Chemother 42 1998 789 794
9. L Edwards A Ferenczy L Eron D Baker ML Owens TL Fox Self-administered topical 5% imiquimod cream for external anogenital warts Arch Dermatol 134 1998 25 30
10. SK Tyring I Arany MA Stanley MA Tomai RL Miller MA Smith A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod J Infect Dis 178 1998 551 555
11. RC Cornell HT Greenway SB Tucker L Edwards S Ashworth JC Vance Intralesional interferon therapy for basal cell carcinoma J Am Acad Dermatol 23 1990 694 700
12. S Toma M Vincenti R Palumbo G Muzio ML Rainero P Santi Results of the association of intralesional recombinant alpha interferon-2a (α-IFN) plus 13- cis -retinoic acid (13cRA) in the treatment of basal cell carcinomas (BCC) of the skin Int J Oncol 3 1993 1149 1154
13. HT Greenway RC Cornell DJ Tanner E Peets GM Bordin C Nagi Treatment of basal cell carcinoma with intralesional interferon J Am Acad Dermatol 15 1986 437 443
14. JK Laihia J Uksila M Luhtala CT Jansen Expression of CD80 (B7/BB-1) and CD28 in human white blood cells treated with urocanic acid Arch Dermatol Res 288 1996 570 574
15. V Vincek Sunlight induced progression of AIDS Med Hypotheses 44 1995 119 123
16. M Liddington AJ Richardson RM Higgins ZH Endre VA Venning JA Murie Skin cancer in renal transplant recipients Br J Surg 76 1989 1002 1005
17. M Norval NK Gibbs J Gilmour The role of urocanic acid in UV-induced immunosuppression: recent advances (1992-1994) Photochem Photobiol 62 1995 209 217
18. M Norval Chromophore for UV-induced immunosuppression: urocanic acid Photochem Photobiol 63 1996 386 390
19. J Uksila JK Laihia CT Jansen Trans -urocanic acid, a natural epidermal constituent, inhibits human natural killer cell activity in vitro Exp Dermatol 3 1994 61 65
20. J Kim RL Modlin RL Moy SM Dubinett T McHugh BJ Nickoloff IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response J Immunol 155 1995 2240 2247
21. SP DeSilva AL Dellon Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study J Surg Oncol 28 1985 72 74
22. JD Richmond RM Davie The significance of incomplete excision in patients with basal cell carcinoma Br J Plast Surg 40 1987 63 67
23. LA Sussman DF Liggins Incompletely excised basal cell carcinoma: A management dilemma? Aust N Z J Surg 66 1996 276 278
24. H Breuninger M Pesch K Dietz G Rassner Quantitative analysis of recurrence and spontaneous regression of basalioma parts left in situ Hautarzt 43 1992 561 565